Analysis of Protein Expression and Gene Mutation of c-kit in Colorectal Neuroendocrine Carcinomas

American Journal of Surgical Pathology

Volumn 27, Issue 12, 2003, Pages 1551-1558

  Akintola Ogunremi, Olaronke ^a   Pfeifer, John D ^a   Tan, Benjamin R ^a   Yan, Yan ^a   Zhu, Xiaopei ^a   Hart, John ^b   Goldblum, John R ^c   Burgart, Lawrence ^d   Lauwers, Gregory Y ^e   Montgomery, Elizabeth ^f   Lewin, David ^g   Washington, Kay ^h   Bronner, Mary ⁱ   Xiao, Shu Yuan ^j   Greenson, Joel K ^k   Lamps, Laura ^l   Lazenby, Audrey ^m   Wang, Hanlin L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l UNIVERSITY OF ARKANSAS   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

C kit; CD117; Colon; Neuroendocrine carcinoma; Small cell carcinoma

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; POLYCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ADENOMA; ADULT; AGED; ARTICLE; C KIT ONCOGENE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CARCINOID; COLORECTAL CARCINOMA; COLORECTAL NEUROENDOCRINE CARCINOMA; CONTROLLED STUDY; DISEASE MARKER; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG SMALL CELL CANCER; MALE; NEUROENDOCRINE TUMOR; ONCOGENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS;

EID: 0344861879     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200312000-00008     Document Type: Article

References (53)

1. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29:498-504.
2. Arteaga CL, Khuri F, Krystal G, et al. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol. 2002;29(1 Suppl 4):15-26.
3. Attoub S, Rivat C, Rodrigues S, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002;62:4879-4883.
4. Barisella M, Andreola S, Rosai J. CD117 in soft tissue sarcomas. Am J Clin Pathol. 2002;118:470-471.
5. Bellone G, Carbone A, Sibona N, et al. Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res. 2001;61:2200-2206.
6. Bellone G, Silvestri S, Artusio E, et al. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol. 1997;172:1-11.
7. Burke AB, Shekitka KM, Sobin LH. Small cell carcinomas of the large intestine. Am J Clin Pathol. 1991;95:315-321.
8. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160:1567-1572.
9. Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466-477.
10. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
11. Féger F, Ribadeau Dumas A, Leriche L. et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002;127:110-114.
12. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459-465.
13. Fletcher CD, Fletcher JA. Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest? Am J Clin Pathol. 2002;118:163-164.
14. Gaffey MJ, Mills SE, Lack EE. Neuroendocrine carcinoma of the colon and rectum. A clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases. Am J Surg Pathol. 1990;14:1010-1023.
15. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol. 2002;9:65-69.
16. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692-1703.
17. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.
18. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6:2291-2296.
19. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188-193.
20. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. CancerRes. 1996;56:370-376.
21. Krystal GW, Honsawek S, Kiewlich D, et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. 2001;61:3660-3668.
22. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319-3326.
23. Lahm H, Amstad P, Yilmaz A, et al. Interleukin 4 down-regulates expression of c-kit and autocrine stem cell factor in human colorectal carcinoma cells. Cell Growth Differ. 1995;6:1111-1118.
24. Lucas DR, Al-Abbadi M, Tabaczka P, et al. c-Kit expression in desmoid fibromatosis: comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol. 2003;119:339-345.
25. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol. 1993;142:339-346.
26. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 2003;9:188-194.
27. Mills SE, Allen MS Jr, Cohen AR. Small-cell undifferentiated carcinoma of the colon. A clinicopathological study of five cases and their association with colonic adenomas. Am J Surg Pathol. 1983;7:643-651.
28. Miettinen M. Are desmoid tumors kit positive [Letter]? Am J Surg Pathol. 2001;25:549-550.
29. Miettinen M. New challenges in the identification of gastrointestinal stromal tumors and other possible KIT-driven tumors. Am J Clin Pathol. 2002;117:183-185.
30. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38(Suppl 5):S39-S51.
31. Montgomery E, Torbenson MS, Kaushal M, et al. β-Catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol. 2002;26;1296-1301.
32. Naeem M, Dahiya M, Clark JI, et al. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol. 2002;33:1182-1187.
33. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184-1197.
34. Öberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(Suppl 2):S3-S8.
35. Onoda N, Kobayashi H, Satake K, et al. Neuroendocrine carcinoma of the sigmoid colon: report of a case. Surg Today. 1999;29:1079-1082.
36. Radford IR. Imatinib. Novartis. Curr Opin Investig Drugs. 2002;3:492-499.
37. Reed J, Ouban A, Schickor FK, et al. Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer. 2002;2:119-122.
38. Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin Oncol. 1999;11:116-122.
39. Saclarides TJ, Szeluga D, Staren ED. Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience. Dis Colon Rectum. 1994;37:635-642.
40. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 1991;51:2416-2419.
41. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res. 1993;53:1709-1714.
42. Sheng ZM, Przygodzki RM, O'Leary TJ. Rapid screening for KIT mutations by capillary electrophoresis. [Letter] Clin Chem. 2001;47:1325-1326.
43. Tian Q, Frierson HF Jr, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643-1647.
44. Toyota M, Hinoda Y, Takaoka A, et al. Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol. 1993;14:295-302.
45. rd ed. Berlin: Springer-Verlag; 1999.
46. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994;424:135-141.
47. Vortmeyer AO, Lubensky IA, Merino MJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89:1448-1453.
48. Wang HL, Goldblum JR, Lauwers GY, et al. Biologic behavior and molecular pathology of colorectal neuroendocrine carcinomas (CNCs). [Abstract] Mod Pathol. 2001;14:98A.
49. Wang HL, Kuan SF, Goldblum JR, et al. Do colorectal neuroendocrine carcinomas arise from preexisting adenomas [Abstract]? Mod Pathol. 2001;14:98A.
50. Wang HL, Wang J, Xiao SY, et al. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing β-catenin. Int J Cancer. 2002;101:301-310.
51. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000;19:3521-3528.
52. Wick MR, Weatherby RP, Weiland LH. Small cell neuroendocrine carcinoma of the colon and rectum: clinical, histologic, and ultrastructural study and immunohistochemical comparison with cloacogenic carcinoma. Hum Pathol. 1987;18:9-21.
53. Yantiss RK, Spiro IJ, Compton CC, et al. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol. 2000;24:947-957.